Introduction
============

Chronic kidney disease (CKD) was prevalent in 25.8 million adults in the United States in 2004 ([@ref-40]). CKD prevalence will increase by 5 million every decade in the United States ([@ref-35]). This alarming increase in CKD prevalence is due to an associated increase in the prevalence of hypertension, type 2 diabetes mellitus and obesity in the United States ([@ref-35]; [@ref-10]; [@ref-9]). CKD, obesity, hypertension and diabetes in unison are estimated to cost the American health care system a sum of \$110 billion annually ([@ref-25]; [@ref-18]).

Heparin acts by accelerating the inhibition of thrombin, and also factors (F) Xa, IXa, XIa and XIIa. Low molecular weight heparins (LMWH) are recently identified, widely used, heparin derivatives with a mean molecular weight of less than 8,000 Daltons ([@ref-21]). Commonly used LMWH are Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin and Tinzaparin ([@ref-12]). They have a lower incidence of heparin induced thrombocytopenia ([@ref-12]; [@ref-13]; [@ref-31]) compared to UH ([@ref-12]). LMWHs, due to the shorter polysaccharide chain show a more pronounced FXa inhibitory profile, have a longer half-life and aids in once-a-day administration. However, action of LMWH depends on the length of the polysaccharide chain and hence, all LMWHs do not show the same inhibitory profile.

Observational studies showed that use of LMWH for prevention of extra-corporeal circuit thrombosis during dialysis sessions and graft or fistula thrombosis post dialysis in end stage renal disease (ESRD) patients were associated with greater bleeding risk compared to UH ([@ref-8]; [@ref-11]). RCTs that assessed efficacy of LMWH had either excluded patients with renal disease or through inadequately powered sub-group analysis, had shown that patients with renal disease may be at risk for increased bleeding events ([@ref-41]). A systematic review and meta-analysis on the same topic was conducted by [@ref-20] in 2004 where they had abstracted data from 17 trials. They concluded that LMWH was as effective and safe as UH in patients with ESRD receiving regular hemodialysis ([@ref-20]). However, as the authors had reported, risk of bias was high for the studies included in their meta-analysis and they were small population studies.

The rationale for our systematic review and meta-analysis are: (1) we have focused our comparison to LMWH and UH only. Our review will be clinically useful since 95% centers around the globe use only these 2 drugs and not citrate as analyzed in the review by [@ref-20], (2) we have focused our review to only those LMWH that are currently approved by the Food and Drug Administration (FDA). Hence, our review will be clinically relevant for US dialysis centers, (3) we have only included studies that had an explicit random allocation. We excluded controlled clinical trials that did not have an explicit random allocation; the review by [@ref-20] had included controlled trials that did not have an explicit random allocation. Hence, it is likely that our estimates are less biased. Hence via this systematic review and meta-analysis we have compared the efficacy and safety of LMWH compared to UH in patients with ESRD receiving outpatient, chronic, intermittent hemodialysis for dialysis associated events (examples: extra-corporeal circuit thrombosis graft/fistula thrombosis and bleeding complications). This review does not attempt to compare the 2 types of heparins for treatment of deep vein thrombosis or pulmonary embolism in these patients.

Methods
=======

The protocol of this study can be found as [Data S1](#supp-7){ref-type="supplementary-material"}. This protocol was approved by the Johns Hopkins Centers for Clinical Trials, Baltimore, Maryland, USA.

Data sources
------------

We searched 3 databases namely: (1) Pubmed, (2) Embase, (3) Cochrane central. We did not use language or date restrictions when we searched for citations. Detailed search strategy has been explained in the Appendix. A librarian from Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA helped us develop the search strategy. Date of last search was 24th November 2014.

Study selection
---------------

Criteria for study inclusion in this review were: (1) RCTs comparing LMWH and UF; we only included studies where the intervention allocation was truly random. Quasi-randomized or any other types of non-random intervention allocation were criteria for exclusion. (2) We included any RCT that used LMWH approved by the FDA; this included Dalteparin, Enoxaparin, and Tinzaparin. (3) The study participants in the included studies were adult patients (age \> 18 years) with end stage renal disease (ESRD), (4) The study participants were receiving chronic, intermittent, out-patient hemodialysis for renal replacement therapy. Only human studies were included. We excluded studies where LMWH was administered to patients not for the indication of anti-coagulation for hemodialysis but for therapy of another condition such as deep vein thrombosis, pulmonary embolism etc. Three reviewers independently assessed studies for eligibility. After title and abstract review, full texts of those citations determined eligible were assessed. From these full text citations, those that satisfied all criteria for inclusion were included in the review. Discrepancy was resolved by consensus.

Outcomes of our review
----------------------

We focused on clinically relevant outcomes as primary outcomes for this review. They were: (1) extracorporeal circuit thrombosis during dialysis session: abstracted as presence or absence (yes/no), (2) graft or fistula thrombosis 7 days after trial drug administration (abstracted as yes/no); rationale being that we expected to remove confounding due to other factors that might play a role in graft and fistula thrombosis and hence 7 days would have been adequate time for the same. Other secondary outcomes considered are: (1) bleeding complications (i.e., intra-cranial hemorrhage, hemorrhagic stroke or any clinically recorded bleeding)---abstracted as number of patients with events; (2) deep vein thrombosis (DVT)---abstracted as number of patients with events; (3) pulmonary embolism (PE) (abstracted as number of patients with events); (4) vascular compression time (abstracted as continuous variable in seconds); (5) lipid profile: (low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), total cholesterol, LDL/HDL ratio))---(abstracted as continuous variables).

Other data abstracted from included studies
-------------------------------------------

Type of RCT (including: year(s) of conduct, total sample size, study duration, date study commenced, place or region of study), study methodology (including eligibility criteria, methods of randomization, type of randomization sequence followed, allocation sequence concealment, and masking, washout period), participant characteristics: total number, setting (hospital based or free-standing), age, sex, country, race, comorbidities (diabetes, hypertension, bleeding disorders, autoimmune disorders), frequency of dialysis, intervention: LMWH and UH (dose, name of drug, route of drug, timing relative to hemodialysis, frequency of administration).

Assessment of risk of bias in included studies
----------------------------------------------

Risk of bias was assessed by two independent reviewers. When there was a discrepancy, it was resolved by consensus. The studies were evaluated for the following criteria: (1) allocation, (2) masking of investigators and participants, (3) masking of outcome assessment, (4) loss to follow-up (attrition) and intention to treat analysis. Details of risk of bias assessment are mentioned in the protocol in the [Supplemental Information](#supplemental-information){ref-type="supplementary-material"}.

Statistical analysis
--------------------

We followed the analysis plan outlined in the protocol. We reported relative risks and 95% confidence intervals of the relative risks for all dichotomous outcomes. For continuous outcomes we calculated means, mean difference and standard deviations. Clinical heterogeneity was determined based on clinical knowledge. Methodological heterogeneity was assessed based on run in period, duration of study, adequacy of randomization etc. Statistical heterogeneity was assessed using *I*^2^. *I*^2^ of 25%, 50% and 75% was considered low, moderate and high heterogeneity respectively. If there were more than 10 included studies in the meta-analysis we had apriori decided to use funnel plots to assess reporting bias. Since our meta-analysis included only 4 studies we did not perform a funnel plot. Studies were pooled with the random effects model as we suspected significant heterogeneity; clinical, and methodological in the studies to be included in the meta-analysis. *P* \< 0.05 was considered statistically significant. Although we had previously planned to do a sub-group analysis based on different types of LMWHs, we were unable to conduct sub-group analysis as planned due to the small number of included studies for meta-analysis. Although we had previously planed to perform sensitivity analysis based on study quality, since all included studies were similarly of poor quality we could not perform this sensitivity analysis.

Results
=======

In total we had 4,095 citations retrieved after searching the three databases. After removing duplicates we were left with a final list of 3,735 citations. Of these, 19 citations were included in the review and 4 were pooled in the meta-analysis. Please refer to [Fig. 1](#fig-1){ref-type="fig"} for the study flow details.

![Article flow diagram.\
Details the process of study inclusion into the review](peerj-03-835-g001){#fig-1}

Characteristics of included studies ([Table 1](#table-1){ref-type="table"})
---------------------------------------------------------------------------

Among the 19 included RCTs ([@ref-1]; [@ref-6]; [@ref-7]; [@ref-14]; [@ref-15]; [@ref-16]; [@ref-19]; [@ref-23]; [@ref-24]; [@ref-26]; [@ref-27]; [@ref-28]; [@ref-30]; [@ref-29]; [@ref-34]; [@ref-37]; [@ref-38]; [@ref-39]; [@ref-44]), 6 had a parallel group design and 13 had a cross-over design. Most regions of the world were represented, with 5 studies from Poland, 2 studies each from Netherland, Germany and United Kingdom and 1 study each from United States, Greece, France, Canada, Sweden, Turkey, Australia and Romania. Seven studies had evaluated enoxaparin, 6 dalteparin, and 5 evaluated tinzaparin. Sample size ranged from 8 to 70 participants. None of the studies explicitly defined a run-in period. Thirteen of the 19 studies had used a fixed LMWH dose and the remaining used a variable dose of LMWH. The fixed dose was usually between 0.69 mg/kg--1 mg/kg. For UH, most studies had used a bolus dose initially and was followed by an infusion. Thirteen studies had used a fixed dose of UH and 6 used variable dose of UH. The fixed dose comprised of 1,500--5,000 IU bolus followed by 36--62 IU/kg infusion.
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###### Characteristics of included studies.

Table details the characteristics of the studies included in the review.

![](peerj-03-835-g004)

  --------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Name of first author**    **Aggarwal**                                          **Borm**                                                                                                                                                             **Elisaf**                                                                                                      **Gritters**                                                            **Harenberg**                            **Hottelart**                                                         **Lane**                                                                                                      **Lord**                                                                                                                                        **Verzan**                                                   **Naumnik**
  **Year**                    2004                                                  1986                                                                                                                                                                 1997                                                                                                            2006                                                                    1995                                     1998                                                                  1986                                                                                                          2002                                                                                                                                            2004                                                         2009
  **Methods**                 Parallel RCT                                          Crossover RCT                                                                                                                                                        Crossover RCT                                                                                                   Crossover RCT                                                           Parallel RCT                             Crossover RCT                                                         Crossover RCT                                                                                                 Crossover RCT                                                                                                                                   Crossover RCT                                                Parallel RCT
  **Participants**            20                                                    10                                                                                                                                                                   36                                                                                                              8                                                                       20                                       11                                                                    8                                                                                                             32                                                                                                                                              66                                                           22
  **Interventions**           Enoxaparin                                            Dalteparin                                                                                                                                                           Tinzaparin                                                                                                      Dalteparin                                                              Dalteparin                               LMWH not specified                                                    Dalteparin                                                                                                    Tinzaparin                                                                                                                                      Tinzaparin                                                   Enoxaparin
  **Dose (fixed/variable)**   Fixed                                                 Fixed                                                                                                                                                                Variable                                                                                                        Fixed                                                                   Fixed                                    Variable                                                              Fixed                                                                                                         Variable                                                                                                                                        Variable                                                     Fixed
  **Country**                 United States                                         Netherlands                                                                                                                                                          Greece                                                                                                          Netherlands                                                             Germany                                  France                                                                United Kingdom                                                                                                Canada                                                                                                                                          Romania                                                      Poland
  **Notes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Difficult to assess randomization groups for outcomes                                                                                                                                                                                                         Abstract-specific data not provided for circuit thrombosis   
  **Outcomes**                ADP-induced fibrinogen binding, platelet reactivity   Extracorporeal circuit thrombosis, bleeding complications, factor Xa levels, platelet function, beta-thromboglobulin, thromboxane A2, platelet factor 4, serotonin   Lipid profile (HDL, LDL, total cholesterol, apo A1, apo B, triglycerides, lipoprotein a), albumin, hemoglobin   Platelet factor 4, polymorphonuclear cells and platelet degranulation   Hep test, aPTT, thrombin clotting time   Plasma aldosterone, renin, aldosterone/renin ratio, serum potassium   Fibrinopeptide A, beta-thromboglobulin, kaolin cephalin clotting time, plasma heparin levels, bleeding time   Extracorporeal circuit thrombosis, bleeding complications, vascular compression time, patient/nurse satisfaction, relative cost, nursing time   Extracorporeal circuit thrombosis                            Thrombomodulin, von-Willebrand factor, plasminogen activator inhibitor 1, cell surface adhesion molecule, e-selectin, intercellular adhesion molecule 1, prothrombin fragment 1 + 2
  --------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  **Name of first Author**    **Mahmood**                                                                         **Naumnik**                                                                                                            **Naumnik**                                                                                                     **Naumnik**                                                          **Naumnik**                                               **Poyrazoglu**                                                                           **Ryan**                                                                    **Saltissi**                                                                                                                                       **Schrader**
  **Year**                    2010                                                                                2003                                                                                                                   2007                                                                                                            2007                                                                 2009                                                      2006                                                                                     1990                                                                        1999                                                                                                                                               1988
  **Methods**                 Crossover RCT                                                                       Parallel RCT                                                                                                           Crossover RCT                                                                                                   Crossover RCT                                                        Crossover RCT                                             Parallel RCT                                                                             Crossover RCT                                                               Crossover RCT                                                                                                                                      Parallel RCT
  **Participants**            20                                                                                  25                                                                                                                     22                                                                                                              22                                                                   22                                                        33                                                                                       8                                                                           36                                                                                                                                                 70
  **Interventions**           Tinzaparin                                                                          Enoxaparin                                                                                                             Enoxaparin                                                                                                      Enoxaparin                                                           Enoxaparin                                                Dalteparin                                                                               Tinzaparin                                                                  Enoxaparin                                                                                                                                         Dalteparin
  **Dose (fixed/variable)**   Fixed                                                                               Fixed                                                                                                                  Fixed                                                                                                           Fixed                                                                Fixed                                                     Fixed                                                                                    Fixed                                                                       Variable                                                                                                                                           Variable
  **Country**                 Sweden                                                                              Poland                                                                                                                 Poland                                                                                                          Poland                                                               Poland                                                    Turkey                                                                                   United Kingdom                                                              Australia                                                                                                                                          Germany
  **Notes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Abstract                                                                                                                                                                                                                       
  **Outcomes**                Lipid profile (LDL, HDL, total cholesterol, triglycerides) and lipoprotein lipase   Pro-thrombotic tissue factor, tissue factor pathway inhibitor, activated coagulation marker prothrombin fragment 1+2   Transforming growth factor beta-1, platelet derived growth factor AB, beta-thromboglobulin, platelet factor 4   Vascular endothelial growth factor, basic fibroblast growth factor   Prothrombin fragment1+2, thrombin/anti-thrombin complex   C-reactive protein, tumor necrosis factor alpha, superoxide dismutase, malondialdehyde   Anti-factor Xa activity, fibrinopeptide A, beta-thromboglobulin, hep test   Extracorporeal circuit thrombosis, bleeding complications, vascular compression time, lipid profile (LDL, HDL, VLDL, triglycerides, cholesterol)   Extracorporeal circuit thrombosis, bleeding complications, lipid profile, factor Xa level, erythrocyte concentration
  --------------------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------

Patient characteristics ([Table 2](#table-2){ref-type="table"})
---------------------------------------------------------------

All study patients were adults (age \> 18 years) with ESRD; ages ranged between 27--43 years. None of the study participants in any of the included studies had hyper-coagulable conditions or were receiving anti-coagulant or anti-platelet drugs. Diabetic nephropathy was the commonest in both these studies (33--36%) followed by hypertensive nephropathy (27%) and then by lupus nephritis (19%). All received regular, maintenance, outpatient hemodialysis. The dialysis frequency ranged between 3--5 sessions every week. Duration of dialysis was 4--5 h. Loss to follow-up ranged between 10--17% in the reported studies. Details of patient characteristics can be seen in [Tables 1](#table-1){ref-type="table"} and [2](#table-2){ref-type="table"}. Comorbid conditions of study participants are detailed in [Table S1](#supp-3){ref-type="supplementary-material"}. The LMWH group and the UH group were similar with regards to the comorbid variables: diabetes prevalence, hypertension prevalence, coronary artery disease prevalence, smoking prevalence, obesity prevalence and dyslipidemia prevalence in most of the included studies ([Table S1](#supp-3){ref-type="supplementary-material"}).

10.7717/peerj.835/table-2

###### Patient characteristics (patients in studies that reported outcomes of interest).

Characteristics of patients in the included studies.

![](peerj-03-835-g005)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, year (reference)   Mean age (yrs) ± SD    Excluded patients   Follow-up duration   Patients lost to follow-up   Patients (*n*): LMWH/UH   Frequency and duration of dialysis   Type of LMWH           Mean LMWH dose   Mean UFH dose      
  ------------------------- ---------------------- ------------------- -------------------- ---------------------------- ------------------------- ------------------------------------ ---------------------- ---------------- ------------------ ----------------------
  [@ref-6]                  58.6                   No                  NS                   NS                           0/0                       10                                   2-3/wk, 4 h            Dalteparin       \(B\) 18 IU/kg;\   \(B\) 36 IU/kg;\
                                                                                                                                                                                                                                (I) 9 IU/kg/h      (I) 18 IU/kg/h

  [@ref-38]                 68.5                   No                  No                   24 weeks                     5                         36                                   3--4/wk, 3--5 h        Enoxaparin       \(B\) 1 mg/kg;\    \(B\) 50 IU/kg;\
                                                                                                                                                                                                                                (I) 0.69 mg/kg/h   (I) 1,000 IU/h

  [@ref-23]                 66.6 ± 14.8            No                  No                   8 weeks                      2                         32                                   3/wk, 3.5--4 h         Tinzaparin       4318 IU            \(B\) 50--75 IU/kg;\
                                                                                                                                                                                                                                                   (I) NS

  [@ref-39]                 54 ± 15.2 (LMWH),\     No                  NS                   12 months                    8                         70 (35/35)                           NS, 4.5--5 h           Dalteparin       \(B\) 34 IU/kg;\   \(B\) 62 IU/kg;\
                            51.6 ± 17.9 (UFH)                                                                                                                                                                                   (I) 12 IU/kg/h     (I) 17 IU/kg

  [@ref-15]                 53.4 ± 19.9 (LMWH),\   NS                  NS                   NS                           NS                        20 (10/10)                           3--4 h, 4/wk           Dalteparin       \(B\) 1750 IU\     \(B\) 2650 IU;\
                            59.1 ± 15.72 (UFH)                                                                                                                                                                                  (I) 26.4 IU/kg     36.6 IU infusion

  [@ref-44]                 NS                     NS                  NS                   NS                           NS                        66                                   3/wk, 4--5 h/session   Tinzaparin       40 IU/kg           Mean dose 6262\
                                                                                                                                                                                                                                                   2300IU/session

  [@ref-24]                 52.1 ± 17.2            NS                  NS                   NS                           NS                        20                                   3/wk, 4--5 h/session   Tinzaparin       \(B\) 34 IU/kg;\   \(B\) 62 IU/kg;\
                                                                                                                                                                                                                                (I) 12 IU/kg/h     (I) 17 IU/kg

  [@ref-14]                 55.2 ± 11.7            NS                  NS                   NS                           NS                        8                                    3/wk, 4--5 h/session   Dalteparin       NS                 \(B\) 62 IU/kg;\
                                                                                                                                                                                                                                                   (I) 17 IU/kg

  [@ref-7]                  57.1 ± 12.3            NS                  NS                   NS                           NS                        36                                   NS                     Tinzaparin       \(B\) 34 IU/kg;\   NS
                                                                                                                                                                                                                                (I) 12 IU/kg/h     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

NSNot specified

Risk of bias in included studies
--------------------------------

Please refer to [Fig. S1](#supp-4){ref-type="supplementary-material"} and [Table S2](#supp-6){ref-type="supplementary-material"} for details of risk of bias assessment. In summary, all included studies in the review were considered to be of poor quality based on risk of bias assessment.

Study outcomes
--------------

### Primary outcomes

None of the included studies assessed graft or fistula thrombosis. Six studies had reported extracorporeal circuit thrombosis, of which the study by [@ref-44], though it had mentioned that the LMWH group and UH group were similar with regards to the number of people with this outcome, did not report the exact numbers. [@ref-15] reported that LMWH group (tinzaparin) did not differ with UH group as both groups had similar number of events (1/10 each). The remaining 4 studies [@ref-6], [@ref-39], [@ref-38] and [@ref-23], had reported this outcome for the total number of dialysis sessions in each group. The number of extracorporeal circuit thrombosis/number of dialysis sessions encountered for the LMWH group in these 4 studies were respectively 4/10, 80/5045, 17/1111 and 32/378 compared to 4/10, 69/5197, 35/1141, 21/382 in the UH group. The risk ratio comparing LMWH to UH in these 4 studies were 1.00 (0.34--2.93), 1.19 \[0.87, 1.64\], 0.50 \[0.28, 0.89\], and 1.54 \[0.90, 2.62\] respectively ([Table 3](#table-3){ref-type="table"}). The pooled risk ratio was 1.00 with a 95% CI \[0.62--1.62\]. ([Fig. 2](#fig-2){ref-type="fig"}).

![Forest plots: extracorporeal circuit thrombosis.\
Forest Plots comparing LMWH Vs UH for extracorporeal circuit thrombosis.](peerj-03-835-g002){#fig-2}
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###### Summary table for meta-analysis (extracorporeal circuit thrombosis).

Table detailing the event rates of comparison between LMWH and UH for extracorporeal circuit thrombosis.

![](peerj-03-835-g006)

  Study       LMWH   UFH     Risk ratio   95% CI          
  ----------- ------ ------- ------------ -------- ------ ------------
  [@ref-6]    4      10      4            10       1.00   0.34--2.93
  [@ref-39]   80     5,045   69           5,197    1.19   0.87--1.64
  [@ref-38]   17     1,111   35           1,141    0.50   0.28--0.89
  [@ref-23]   32     378     21           382      1.54   0.90--2.62
  Total       133    6,544   129          6,730    1.00   0.62--1.62

### Secondary outcomes

Of the secondary outcomes, deep vein thrombosis and pulmonary embolism were not reported by any of the included studies. Two studies ([@ref-23]; [@ref-38]) had addressed vascular compression times. The vascular compression times for LMWH (Tinzaparin) (9.5 ± 3.0 min) compared to UH (9.5 min ± 1.8 min) were similar in the study by [@ref-23]. In [@ref-38], vascular compression time for LMWH (enoxaparin) (388 ± 164 s) was similar to that for UH (331 ± 135 s). In total there were 5 studies that had addressed one or more of the lipid profile components. The study by [@ref-24] had reported acute changes in triglyceride levels during dialysis with LMWH (Tinzaparin) compared with UH. However, [@ref-38], reported lipid changes at 12 weeks and observed that there were no differences in the lipid changes from baseline when LMWH (enoxaparin) was compared to UH for LDL, HDL, total cholesterol, VLDL and triglycerides. However, [@ref-39] reported that UF group had significantly higher triglyceride and VLDL cholesterol levels compared to UH group (Fragmin) (*P* \< 0.05) at the end of 12 months but the groups were similar with LDL and HDL levels. [@ref-14] observed that there were no differences between the LMWH group and the UH group with regards to LDL levels measured at 1 week after study initiation. [@ref-7] showed that total cholesterol, triglycerides, LDL cholesterol and total cholesterol/HDL ratio significantly decreased after LMWH (Tinzaparin) switch from UH at 3 months, 6 months and 12 months but HDL cholesterol did not significantly change during this period. Four studies had reported bleeding complications ([@ref-6]; [@ref-39]; [@ref-38]; [@ref-23]). The number of events/patient in each group were respectively 2/10, 3/32, 12/36, and 19/35 for the LMWH group and 1/10, 8/32, 6/36 and 16/35 for the UFH group. The risk ratio for bleeding in the LMWH group for [@ref-6]; [@ref-39]; [@ref-38]; [@ref-23] compared to UFH were respectively 2.00 (0.21--18.69), 0.38 (0.11--1.29), 2.00 (0.84--4.75) and 1.19 (0.74--1.90) ([Table 4](#table-4){ref-type="table"}). The pooled risk ratio from meta-analysis of these 4 studies was 1.16 (0.62--2.15) ([Fig. 3](#fig-3){ref-type="fig"}).

![Forest plots: bleeding complications.\
Forest plots comparing LMWH Vs UH for bleeding complications.](peerj-03-835-g003){#fig-3}
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###### Summary table for meta-analysis (bleeding complications).

Table details the event rates comparison between LMWH and UH for bleeding complications.

![](peerj-03-835-g007)

  Study       LMWH   UFH   Risk ratio   95% CI          
  ----------- ------ ----- ------------ -------- ------ -------------
  [@ref-6]    2      10    1            10       2.00   0.21--18.69
  [@ref-39]   19     35    16           35       1.19   0.74--1.90
  [@ref-38]   12     36    6            36       2.00   0.84--4.75
  [@ref-23]   3      32    8            32       0.38   0.11--1.29
  Total       36     113   31           113      1.16   0.62--2.15

Discussion
==========

In this systematic review and meta-analysis we observed that LMWH was similar to UH with regards to extra-corporeal circuit thrombosis and bleeding complications. We did not find studies that assessed graft/fistula thrombosis and prevention of deep vein thrombosis and prevention of pulmonary embolism

To the best of our knowledge only 1 other review by [@ref-20] has been published in this similar topic. The important differences with that review are: (1) they had used LMWH that was approved in Canada and we had used LMWH approved in the United States. Hence, 5 trials that had used Nadroparin (LMWH approved in Canada but not in the US) were not included in our review ([@ref-17]; [@ref-36]; [@ref-42]; [@ref-32]; [@ref-22]), (2) they had used studies that had citrate and other anti-coagulants as control group whereas; we preferred to use only UH as control. Hence, 3 more trials that they had used were not in our review for this reason ([@ref-4]; [@ref-33]; [@ref-5]; [@ref-2]; [@ref-3]), (3) They had used factor Xa levels as one of the outcomes that denoted adequacy of action of LMWH, but with the current available evidence, factor Xa levels have been found not useful in clinical monitoring of LMWH efficacy and hence we opted not to use this outcome for our analysis ([@ref-43]). However, similar to their review, we found that LMWH was similar to UH with respect to efficacy (extracorporeal circuit thrombosis) and safety (bleeding complications) with LMWH approved for use in the US. However, since their review had larger number of studies included for meta-analysis, their sample size was larger, and hence estimates were more precise than ours. Only the study by [@ref-38] showed LMWH to be strongly protective for extracorporeal thrombosis, while our pooled estimate and that by the review by [@ref-20] showed null association. The reason for this observation is unclear. There was no obvious difference between this study and the other studies. It might just mean there was a sampling variability in this study as adequacy of dialysis and severity of uremia was not reported in this study. Also, among the LMWHs, Tinzaparin is preferred in ESRD patients considering its higher molecular weight and lesser dependence on renal functions for elimination from the body. However, due to small number of studies included in the meta-analysis, a subgroup analysis assessing individual LMWHs was not possible. Hence, more RCTs are needed to assess comparative efficacy of one LMWH over the other.

Though we searched three large databases for this review, 5 non-English citations were excluded also, 25 citations were un-retrieved so far. Further, we only included trials that had explicitly mentioned random allocation. It is possible that some trials, though random allocation was not mentioned, may have actually randomized their participants. Hence, due to all these factors it is possible that our final included citations may not be all inclusive. However, since this is possibly random and does not have a systematic component to it, it can tilt the effect estimate more towards null. Hence, more extensive search is needed before we draw conclusions from the study.

Small sample size was an important limitation of our included trials. Not only does it reduce the precision of our estimates, it creates doubts if the randomization was indeed adequate. Some included studies had just 8 to 12 patients, and it is possible that randomization did not work properly and hence some confounding still remained. Further, blinding of outcome determination was unclear and attrition was largely unreported in most trials. Also, there was significant clinical, statistical and methodological heterogeneity in the patient characteristics and the outcome determination. Hence, it is possible that biases like observer bias, could have existed in our results and our pooled analysis. Also, considering the research question it is likely that this proposed observer bias might have been for the LMWH groups as investigators expect more bleeding in this group. This ideally should have shifted the effect estimate more in favor of LMWH. But our results showing null association are reassuring because even in the presence of observer bias favoring LMWH our results show null association.

Since most studies included for the review were of poor quality, better RCTs with larger sample size, better randomization protocol and reporting should be conducted. It is surprising that even though these 3 drugs are approved by the FDA, only one of the studies were conducted in the United States ([@ref-26]). In effect, we are using drugs on American people based on trials conducted elsewhere. Although the other studies did involve patients of European descent, it is essential to retest this RCT with other ethnic groups in the US because FDA approval is not specific to European Americans but for every other ethnicity.

Conclusions
===========

From our review findings and those from Lim et al., we may infer that it may be safe to use the three FDA approved LMWH in ESRD patients, without known hypercoagulable states other than the ESRD that they suffer, receiving regular intermittent hemodialysis.
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